These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17377918)

  • 1. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
    Al-Batran SE; Atmaca A; Schleyer E; Pauligk C; Hosius C; Ehninger G; Jäger E
    Cancer; 2007 May; 109(9):1897-904. PubMed ID: 17377918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
    Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
    Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
    Marshall JL; Richmond E; DeLap RJ
    Clin Cancer Res; 1996 Sep; 2(9):1475-80. PubMed ID: 9816323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.
    Souglakos J; Kakolyris S; Vardakis N; Androulakis N; Mavroudis D; Vamvakas L; Kouroussis C; Agelaki S; Saridaki Z; Georgoulias V
    Cancer Invest; 2005; 23(6):505-10. PubMed ID: 16203658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
    Wilson PM; El-Khoueiry A; Iqbal S; Fazzone W; LaBonte MJ; Groshen S; Yang D; Danenberg KD; Cole S; Kornacki M; Ladner RD; Lenz HJ
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):979-88. PubMed ID: 20062993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer.
    Kouroussis C; Kalbakis K; Androulakis N; Agelaki S; Vamvakas L; Malas K; Souglakos J; Vardakis N; Georgoulias V
    Anticancer Res; 2004; 24(6):4217-21. PubMed ID: 15736475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer.
    Michael M; Zalcberg J; Gibbs P; Lipton L; Gouillou M; Jefford M; McArthur G; Copeman M; Lynch K; Tebbutt NC
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):321-30. PubMed ID: 23108698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
    Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
    Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
    Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
    Kundel Y; Purim O; Figer A; Stemmer SM; Tichler T; Sulkes J; Sulkes A; Brenner B
    Med Sci Monit; 2008 Apr; 14(4):CR190-5. PubMed ID: 18376346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
    Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
    Spigel D; Jones S; Hainsworth J; Infante J; Greco FA; Thompson D; Doss H; Burris H
    Cancer Invest; 2011 May; 29(4):308-12. PubMed ID: 21469980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
    Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.